Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
18h
GlobalData on MSNFDA puts clinical hold on BioNTech’s malaria vaccine trialThe FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technologyâ„¢ platform to rapidly optimize and derisk drug discovery and development, ...
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results